

Food and Drug Administration Silver Spring MD 20993

NDA 021436/S-041 NDA 021713/S-032 NDA 021729/S-024 NDA 021866/S-026 NDA 202971/S-009

### SUPPLEMENT APPROVAL

Otsuka Pharmaceutical Development & Commercialization, Inc. U.S. Agent for Otsuka Pharmaceutical Company, Ltd. Attention: Dana Cahill, PhD Associate Director, Global Regulatory Affairs 2440 Research Boulevard Rockville, MD 20850

### Dear Dr. Cahill:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received July 14, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Abilify (aripiprazole) 2, 5, 10, 15, 20, 30 mg tablets (NDA 021436); Abilify (aripiprazole) 1 mg/mL oral solution (NDA 021713); Abilify (aripiprazole) 10 and 15 mg Orally Disintegrating Tablets (NDA 021729); Abilify (aripiprazole) 9.75 mg/1.3 mL injection for IM use (NDA 021866); Abilify Maintena (aripiprazole) for extended-release injectable suspension, for intramuscular injection 300 mg/vial and 400 mg/vial (NDA 202971).

We also refer to our letter dated May 3, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for aripiprazole, pertaining to the risk of impulse-control problems.

These supplemental new drug applications provide for revisions to the to the Highlights, Warnings and Precautions (5), Patient Counseling Information section (17), and Medication Guide consistent with our May 3, 2016 letter.

# **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your July 14, 2016, submission includes final printed labeling (FPL) for your package insert and Medication Guide. We have not reviewed this FPL. You are responsible for

assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

# WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

# CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U CM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion (OPDP) 5901-B Ammendale Road Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

 $\frac{http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf}{CM443702.pdf}).$ 

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
Information and Instructions for completing the form can be found at
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf.
For more information about submission of promotional materials to the Office of Prescription Drug
Promotion (OPDP), see <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm</a>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf</a>).

## REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDAs 021436/S-041, 021713/S-032, 021729/S-024, 021866/S-026, and 202971/S-009 Page 4

If you have any questions, contact Danbi Lee, Regulatory Project Manager, at (240) 402-8986.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, MD Director Division of Psychiatry Products Office of Drug Evaluation I Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.
/s/
MITCHELL V Mathis 08/18/2016